Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 8/2015

01-08-2015 | Original Article

Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Authors: S. Pelletier, C. B. Confavreux, J. Haesebaert, F. Guebre-Egziabher, J. Bacchetta, M.-C. Carlier, L. Chardon, M. Laville, R. Chapurlat, G. M. London, M.-H. Lafage-Proust, D. Fouque

Published in: Osteoporosis International | Issue 8/2015

Login to get access

Abstract

Summary

We found for the first time that in maintenance hemodialysis patients, higher sclerostin serum level was associated with severe abdominal aortic calcification (AAC). In addition, cortical bone microarchitecture (density and thickness) assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT) at tibia was also independently associated with severe AAC. These results suggest that sclerostin may be involved in the association of mineral and bone disorder with vascular calcification in hemodialysis patients.

Introduction

Severe abdominal aortic calcifications are predictive of high cardiovascular mortality in maintenance hemodialysis (MHD) patients. In patients with end-stage renal disease, a high aortic calcification score was associated with lower bone turnover on bone biopsies. Thus, we hypothesized that sclerostin, a Wnt pathway inhibitor mainly secreted by osteocytes and acting on osteoblasts to reduce bone formation, may be associated with vascular calcifications in MHD patients.

Methods

Fifty-three MHD patients, aged 53 years [35–63] (median [Q1–Q3]) were included. Serum was sampled before the MHD session to assay sclerostin. Framingham score was computed and the abdominal aortic calcification (AAC) score was assessed according to Kauppila method on lateral spine imaging using DEXA. Tibia bone status was evaluated by high-resolution peripheral quantitative computed tomography (HR-pQCT). Patients were distributed into two groups according to their AAC score: patients with mild or without AAC (score below 6) versus patients with severe AAC (score of 6 and above).

Results

In multivariate analysis, after adjustment on age, dialysis duration and diabetes, serum sclerostin and cortical thickness were independently associated with severe AAC (odds ratio (OR) = 1.43 for each 0.1 ng/mL increase [95 % confidence interval (CI) 1.10–1.83]; p = 0.006 and 0.16 for 1 SD increase [0.03–0.73]; p = 0.018, respectively). A second cardiovascular model adjusted on Framingham score and the above mentioned confounders showed similar results.

Conclusions

Elevated sclerostin serum level and poorer tibia cortical bone structure by HR-pQCT were positively and independently associated with higher odds of severe AAC in MHD patients. Serum sclerostin may become a biomarker of mineral and bone disorder and vascular risk in MHD patients.
Appendix
Available only for authorised users
Literature
1.
London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731–1740PubMedCrossRef
2.
Wilson PW, Kauppila LI, O’Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA (2001) Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 103:1529–1534PubMedCrossRef
3.
Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2008) Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 23:586–593PubMedCrossRef
4.
London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943–1951PubMedCrossRef
5.
Shroff R, Long DA, Shanahan C (2013) Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 24:179–189PubMedCrossRef
6.
Kramer I, Keller H, Leupin O, Kneissel M (2010) Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 21:237–244PubMedCrossRef
7.
Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W (2005) A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 36:943–947PubMedCrossRef
8.
Balemans W, Van Hul W (2004) Identification of the disease-causing gene in sclerosteosis–discovery of a novel bone anabolic target? J Musculoskelet Neuronal Interact 4:139–142PubMed
9.
Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844PubMed
10.
Baron R, Rawadi G, Roman-Roman S (2006) Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 76:103–127PubMedCrossRef
11.
Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M (2012) Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 27:226–230PubMedCrossRef
12.
Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8:819–823PubMedCentralPubMedCrossRef
13.
Sabbagh Y, Graciolli FG, O’Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC (2012) Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27:1757–1772PubMedCrossRef
14.
Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM (2006) Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47:1707–1712PubMedCentralPubMedCrossRef
15.
Roman-Garcia P, Carrillo-Lopez N, Fernandez-Martin JL, Naves-Diaz M, Ruiz-Torres MP, Cannata-Andia JB (2010) High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 46:121–128PubMedCrossRef
16.
Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 6, e19595PubMedCentralPubMedCrossRef
17.
Nickolas TL, Stein E, Cohen A, Thomas V, Staron RB, McMahon DJ, Leonard MB, Shane E (2010) Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 21:1371–1380PubMedCentralPubMedCrossRef
18.
Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW (1997) New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 132:245–250PubMedCrossRef
19.
Szulc P, Hofbauer LC, Rauner M, Goettsch C, Chapurlat R, Schoppet M (2012) Serum myostatin levels are negatively associated with abdominal aortic calcification in older men: the STRAMBO study. Eur J Endocrinol 167:873–880PubMedCrossRef
20.
Szulc P, Samelson EJ, Sornay-Rendu E, Chapurlat R, Kiel DP (2012) Severity of aortic calcification is positively associated with vertebral fracture in older men–a densitometry study in the STRAMBO cohort. Osteoporos Int 24:1177–1184PubMedCentralPubMedCrossRef
21.
Sullivan LM, Massaro JM, D’Agostino RB Sr (2004) Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 23:1631–1660PubMedCrossRef
22.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMedCrossRef
23.
Boutroy S, Bouxsein ML, Munoz F, Delmas PD (2005) In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 90:6508–6515PubMedCrossRef
24.
Morales-Santana S, Garcia-Fontana B, Garcia-Martin A, Rozas-Moreno P, Garcia-Salcedo JA, Reyes-Garcia R, Munoz-Torres M (2013) Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 36:1667–1674PubMedCentralPubMedCrossRef
25.
Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML (2013) The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 56:42–47PubMedCrossRef
26.
Claes KJ, Viaene L, Heye S, Meijers B, d’Haese P, Evenepoel P (2013) Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab 98:3221–3228PubMedCrossRef
27.
Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G (2012) Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 90:473–480PubMedCrossRef
28.
Brandenburg VM, Kramann R, Koos R, Kruger T, Schurgers L, Muhlenbruch G, Hubner S, Gladziwa U, Drechsler C, Ketteler M (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219PubMedCentralPubMedCrossRef
29.
Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K (2008) Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19:2193–2203PubMedCentralPubMedCrossRef
30.
Schoppet M, Shanahan CM (2008) Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? Kidney Int 73:989–991PubMedCrossRef
31.
Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99:248–255PubMedCrossRef
32.
Confavreux CB (2011) Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int Suppl 121:S14–S19
33.
Confavreux CB, Szulc P, Casey R, Boutroy S, Varennes A, Vilayphiou N, Goudable J, Chapurlat RD (2013) Higher serum osteocalcin is associated with lower abdominal aortic calcification progression and longer 10-year survival in elderly men of the MINOS cohort. J Clin Endocrinol Metab 98:1084–1092PubMedCrossRef
34.
Kogawa M, Wijenayaka AR, Ormsby RT, Thomas GP, Anderson PH, Bonewald LF, Findlay DM, Atkins GJ (2013) Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J Bone Miner Res 28:2436–2448PubMedCrossRef
35.
Davies MR, Hruska KA (2001) Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 60:472–479PubMedCrossRef
36.
Shanahan CM (2005) Mechanisms of vascular calcification in renal disease. Clin Nephrol 63:146–157PubMedCrossRef
37.
38.
Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM (2008) Exploring the biology of vascular calcification in chronic kidney disease: what’s circulating? Kidney Int 73:384–390PubMedCrossRef
39.
Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M (2010) Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 9:2048–2062PubMedCentralPubMedCrossRef
40.
Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA (2005) Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 115:1210–1220PubMedCentralPubMedCrossRef
41.
Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD (2013) Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 24:489–494PubMedCrossRef
42.
Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, Zhou J, Zhang J, Liao E (2012) Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf) 76:797–801CrossRef
43.
Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR (2012) Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 97:2027–2032PubMedCentralPubMedCrossRef
44.
Szulc P, Boutroy S, Vilayphiou N, Schoppet M, Rauner M, Chapurlat R, Hamann C, Hofbauer LC (2013) Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res 28:1760–1770PubMedCrossRef
45.
Moe SM, Chen NX, Newman CL, Organ JM, Kneissel M, Kramer I, Gattone VH 2nd, Allen MR (2015) Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res 30:539–549CrossRef
46.
Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D’Haese PC (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28:3024–3030PubMedCrossRef
47.
48.
Mieczkowska A, Basle MF, Chappard D, Mabilleau G (2012) Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem 287:23517–23526PubMedCentralPubMedCrossRef
49.
Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA (2012) FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 23:2017–2025PubMedCrossRef
50.
51.
Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M (2013) Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83:1159–1168PubMedCentralPubMedCrossRef
52.
Schousboe JT, Wilson KE, Hangartner TN (2007) Detection of aortic calcification during vertebral fracture assessment (VFA) compared to digital radiography. PLoS One 2, e715PubMedCentralPubMedCrossRef
53.
Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, Yatomi Y, Fukumoto S, Fujita T, Shimosawa T (2014) Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int 85:1103–1111PubMedCrossRef
Metadata
Title
Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?
Authors
S. Pelletier
C. B. Confavreux
J. Haesebaert
F. Guebre-Egziabher
J. Bacchetta
M.-C. Carlier
L. Chardon
M. Laville
R. Chapurlat
G. M. London
M.-H. Lafage-Proust
D. Fouque
Publication date
01-08-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 8/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3127-9

Other articles of this Issue 8/2015

Osteoporosis International 8/2015 Go to the issue

Original Article

Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry

Editorial

Overdiagnosis of osteoporosis: fact or fallacy?

Original Article

Serum 25-hydroxyvitamin D level and risk of falls in Japanese community-dwelling elderly women: a 1-year follow-up study

Original Article

Fracture predictive ability of physical performance tests and history of falls in elderly women: a 10-year prospective study

Original Article

The relationship of thoracic kyphosis to gait performance and quality of life in women with osteoporosis

Letter

Incidence of fracture events with teriparatide: role of study design